Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275021 | 0.89 | CYP11B1 (0.57) | CYP11B1CYP11B2PDE10AHSD11B1KMT2A | |
| SCHEMBL13098202 | 0.89 | CYP11B1 (0.51) | CYP11B1CYP11B2PDE10AHSD11B1MAPT | |
| Perchlorate SCHEMBL11788583 | 0.81 | CYP11B1 (0.46) | CYP11B1CYP11B2PDE10AHSD11B1MAPT | |
| SCHEMBL27549688 | 0.81 | CYP11B1 (0.56) | CYP11B1CYP11B2PDE10AHSD11B1KMT2A | |
| SCHEMBL15635313 | 0.81 | CYP11B1 (0.57) | CYP11B1CYP11B2PDE10AHSD11B1KMT2A | |
| SCHEMBL4903796 | 0.78 | CYP11B1 (0.56) | CYP11B1CYP11B2PDE10AHSD11B1KMT2A | |
| SCHEMBL10190913 | 0.78 | CYP11B1 (0.54) | CYP11B1CYP11B2PDE10AHSD11B1KMT2A | |
| SCHEMBL17069344 | 0.78 | CYP11B1 (0.54) | CYP11B1CYP11B2PDE10AHSD11B1KMT2A | |
| SCHEMBL5549267 | 0.76 | MAPT (0.44) | MAPTCTSKRAB9A | |
| SCHEMBL2050759 | 0.74 | ALDH1A1 (0.43) | PDE10AKMT2AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822337-B2 | TGF-β inhibitorC | RIGEL PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | CYP11B1 950/4885CYP11B2 918/4885PDE10A 1676/4885 |
| US-10822337-B2 | TGF-β inhibitorC | TGFBR1, TGFBR2, TGFB1 | CYP11B1 1757/4885CYP11B2 1886/4885PDE10A 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.